Guanine nucleotide-binding protein subunit alpha-11 (GNA11) (GNA11)

Guanine nucleotide-binding protein subunit alpha-11 (GNA11) is a member of the Gq class of heterotrimeric G protein alpha subunits that functions as a critical transducer in G protein-coupled receptor (GPCR) signaling (UniProt, NIH). It mediates the activation of phospholipase C-beta, leading to the release of intracellular calcium and the activation of protein kinase C (PKC) and the mitogen-activated protein kinase (MAPK) pathway (NIH, MDPI). Somatic gain-of-function mutations in GNA11, particularly at the Q209 and R183 hotspots, are primary oncogenic drivers in nearly half of all uveal melanomas and are also implicated in blue nevi and mucosal melanomas (NIH, PubMed). These mutations result in constitutive signaling that promotes uncontrolled cell proliferation and survival (MDPI). Beyond oncology, germline mutations in GNA11 are linked to disorders of calcium homeostasis, including autosomal dominant hypocalcemia type 2 and familial hypocalciuric hypercalcemia type 2 (MedlinePlus, NIH). Therapeutic efforts focus on inhibiting GNA11 directly or targeting downstream effectors such as PKC, MEK, and YAP (NIH, ResearchGate). However, the ubiquitous expression of GNA11 presents significant safety challenges, as systemic inhibition may lead to widespread toxicity, necessitating precise therapeutic windows or localized delivery strategies (MDPI, NIH).

Other names

G alpha-11GNA-11G protein subunit alpha 11GA11

Direct inhibition of the G alpha-11 subunit or inhibition of downstream signaling pathways such as PKC, MEK, and YAP to block constitutive oncogenic signaling.